Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TFF Pharmaceuticals Inc TFFP

Healthcare
TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaging patented rapid freezing technology to develop and transform medicine into potent dry powder. It is focused on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform. Its TFF technology platform has an applicability to convert any drug, including vaccines, small and large molecules, and biologics, into a dry powder for inhalation, or for topical delivery to the eyes, nose and the skin. TFF Pharmaceuticals has two lead drug candidates in the clinic: TFF TAC (Tacrolimus Inhalation Powder) and TFF VORI (Voriconazole Inhalation Powder). TFF TAC is an inhaled dry powder formulation of tacrolimus, for the prophylaxis of organ rejection in patients receiving lung transplants, in combination with other immunosuppressants. TFF VORI is an inhaled dry powder formulation of voriconazole, for the treatment and prophylaxis of invasive pulmonary aspergillosis.


NDAQ:TFFP - Post by User

TFF Pharmaceuticals Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(170)
•••
Post by whytestockson Apr 29, 2024 9:00pm
64 Views
Post# 36013847

TFF Pharmaceuticals Announces Pricing of $4.8 Million Public

TFF Pharmaceuticals Announces Pricing of $4.8 Million Public
NEWS: $TFFP TFF Pharmaceuticals Announces Pricing of $4.8 Million Public OfferingFORT WORTH, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the &#x201C;Company&#x201D; or &#x201C;TFF Pharmaceuticals&#x201D;), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented T...TFFP - TFF Pharmaceuticals Announces Pricing of $4.8 Million Public Offering

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities